New drug combination doubles down on Alzheimer's treatments
Study finds pairing antibody therapy with molecules found in some common foods is more effective and could cause fewer side effects
Study finds pairing antibody therapy with molecules found in some common foods is more effective and could cause fewer side effects
By Media RelationsA new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.
Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment. They found that it neutralized the clumping of proteins that accumulate in the brain, leading to better outcomes.
Alzheimer’s is the major cause of dementia. Dementia affects nearly 750,000 people in Canada, with a million cases expected by 2030. Alzheimer’s has no cure and current medications only relieve a patient’s symptoms. Anti-amyloid antibody therapies on their own can slow the disease, but they also come with risks that can be fatal, including brain swelling and bleeding.
“We already know the small molecules resveratrol or curcumin, which are found in some common foods, block the buildup of amyloid,” said Dr. Praveen Nekkar Rao, a professor in the School of Pharmacy at Waterloo. “What’s new and exciting is our combination of these molecules with the anti-amyloid antibodies. This approach could allow clinicians to use lower doses of antibodies, potentially reducing the risk of serious treatment-related side effects.”
Since there are few effective treatments for Alzheimer’s, researchers at Waterloo studied whether using two treatments together could work better than using just one. They chose resveratrol and curcumin because they are natural compounds known to reduce amyloid buildup and inflammation.
“I was inspired by chemotherapy, which involves taking multiple medications for effective treatment,” Nekkar Rao said. “Alzheimer’s is a complex disease, but there are very few combination therapy approaches. Our results show that the way forward is definitely combination therapy.”
The researchers emphasize that the study does not suggest that people should start consuming resveratrol or curcumin to prevent or treat dementia. You would have to consume an unsafe amount in order to reach the brain. The next phase of the research will focus on designing next-generation drugs that can reach the brain more effectively, interact favourably with amyloids and pair seamlessly with antibody treatments.
The study appears in ACS Chemical Neuroscience.

Dr. Melanie Campbell and graduate student Lyndsy Acheson study an image of a retina. They are looking for protein deposits found in association with brain diseases, such as Alzheimer's, FTLD-TDP and ALS (University of Waterloo).
Read more
Researchers show retinal images can accurately differentiate ALS and Alzheimer’s, increasing possibility of earlier diagnosis

Dr. Travis Craddock, professor and Canada Research Chair, says the team's findings change our basic knowledge of biology (University of Waterloo).
Read more
New study reveals quantum-level effects in biology with major implications for treatment of some brain diseases

Read more
New evidence-based classification rules expand access and improve fairness for Para Cross Country and Para Alpine skiers
The University of Waterloo acknowledges that much of our work takes place on the traditional territory of the Neutral, Anishinaabeg, and Haudenosaunee peoples. Our main campus is situated on the Haldimand Tract, the land granted to the Six Nations that includes six miles on each side of the Grand River. Our active work toward reconciliation takes place across our campuses through research, learning, teaching, and community building, and is co-ordinated within the Office of Indigenous Relations.